CARDIOVASCULAR HEALTH

Northwestern Medicine Bluhm Cardiovascular Institute has an enduring commitment to improving the heart health of our patients through expert care, advanced education and scientific breakthroughs.

As one of the top 10 cardiology, heart and vascular surgery programs in the U.S.¹ and among the top 20 cardiac surgery programs in the world,² we’re proud that our rankings reflect the exceptional outcomes achieved by our multidisciplinary team. Northwestern Memorial Hospital anchors this excellence as the No. 2 hospital nationally for quality and accountability.³
 
  1. Northwestern Memorial Hospital, U.S. News & World Report, 2026 – 2027
  2. Northwestern Memorial Hospital, Newsweek, 2025
  3. Northwestern Memorial Hospital, No. 2 nationwide within participating comprehensive academic medical centers in the 2025 Vizient Quality and Accountability Ranking
​Over the past two decades, Northwestern Medicine Bluhm Cardiovascular Institute has evolved into an international leader in breakthrough research, advanced technology and exceptional patient care. This report reflects on two decades of innovation, while looking ahead to the next chapter. Read our annual report below.

A Second Chance at Life

Northwestern Medicine Cardiology and Cardiac Surgery teams collaborated with the Tumor Board to remove a rare, football sized heart tumor. Hear Mike’s story.
Northwestern Memorial Hospital has one of the top 10 cardiology, heart and vascular surgery programs in the U.S. Learn more about Northwestern Medicine.

Updates from Northwestern medicine CARDIOVASCULAR

Join Anita W. Asgar, MD, and Jyothy J. Puthumana, MD, in the Cardiac Catheterization Lab as they perform a MitraClip™ procedure on a clinically complex patient with severe mitral regurgitation.

REFER A PAtiENT USING FAST

Northwestern Medicine Bluhm Cardiovascular Institute provides a streamlined experience for referring physicians and their patients. From your first call, our team is here to guide your patient’s journey at every step using a program called FAST.
Within 24 hours of your first call to Bluhm Cardiovascular Institute, a virtual intake visit is scheduled with a nurse coordinator. They will be the patient’s point of contact and guide them through scheduling, testing, the clinic, and any necessary procedures. The nurse coordinator connects with advanced practice providers, physicians and new patient coordinators to draft a clearly defined workflow.

By providing this clinical touchpoint, the FAST program streamlines the patient experience process by:
  • Optimizing clinic visits
  • Avoiding unnecessary testing
  • Ensuring timely and appropriate operations

Our goal is ensuring that the right patient undergoes the right testing, at the right time and with the right intervention as clinically needed.

​To refer a patient or to learn more about Northwestern Medicine Bluhm Cardiovascular Institute, call 312.695.FAST (312.695.3278) or click 'REFER TO US' below to fill out our referral form and a nurse navigator will respond within 24 hours.

MEET THE TEAMS

Clinical trials in CARDIOVASCULAR

Currently over 75 percent of Bluhm Cardiovascular Institute faculty are involved in clinical research. Our clinical research portfolio includes over 100 ongoing clinical trials, with 65 actively enrolling. To view all clinical trials, visit Bluhm Cardiovascular Institute -- Clinical Trials Unit.

CLEOPATTRA

The purpose of this study is to evaluate whether the investigational medication NNC6019-0001, compared with placebo, reduces the risk of cardiovascular death and major cardiovascular events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including both variant ATTR-CM (ATTRv-CM) and wild-type ATTR-CM (ATTRwt-CM). Participants will be randomized in a 1:1 ratio to receive either NNC6019-0001 or placebo administered by intravenous (IV) infusion every 4 weeks for an anticipated treatment duration of up to 48 months.
Principal Investigator:
Ravi B. Patel, MD, MSc

PARADIGM

The objective of this study is to establish safety and effectiveness of the DurAVR® Transcatheter Heart Valve (THV) in patients with severe calcific aortic stenosis who are determined to have an indication for transcatheter aortic valve replacement (TAVR). Participants will be randomized 1:1 to receive either TAVR using the DurAVR® THV System or TAVR using any commercially available and approved THV. Participants with a failed surgical bioprosthesis who are high surgical risk and need valve-in-valve (ViV) TAVR will be enrolled in a separate nested registry and will only receive the DurAVR THV. Participants will be followed at 30 days, 6 months, 1 year and annually through 10 years.
Principal Investigator:
Anita W. Asgar, MD

Follow Northwestern Medicine CARDIOVASCULAR


  1. Northwestern Memorial Hospital, U.S. News & World Report, 2025 – 2026
  2. Northwestern Memorial Hospital, Newsweek, 2025
  3. Northwestern Memorial Hospital, ranked No. 2 in the 2025 Vizient Quality and Accountability Ranking.